N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.
Goldberg
Richard M
RM
Mayo Clinic, Rochester, MN, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage*; D008297:Male; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D010166:Palliative Care / Q000379:methods*; D011725:Pyridines / Q000008:administration & dosage*; D016019:Survival Analysis
D009944:Organoplatinum Compounds; D011725:Pyridines; C431073:oxiplatin; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin